Patients with sickle cell disease (SCD) manage most pain symptoms or events at home without seeking medical help (Smith et al, 2008) . Thus, to have the largest impact on patients' functioning and quality of life, we should focus more on assessment and treatment of daily pain rather than episodic acute pain that requires emergent care (Amr et al, 2011) . We need innovative approaches to better understand daily pain patterns and factors associated with changes in pain intensity and frequency. In the current study, we use a mobile e-diary app to describe day-to-day patterns in SCDrelated pain symptoms and identify the clinical and demographic factors associated with differences in daily pain level among adult patients with SCD.
Three sickle cell centres, located in large urban medical centres, used the sickle cell Mobile Application to Record symptoms via Technology (SMART) for ongoing studies. This study combines data from two independent clinical trials with similar daily pain tracking protocols (NCT01833702, NCT02384590). The trial conducted at University of Pittsburgh (Pitt) and Vanderbilt University (Vanderbilt) asked participants to use SMART for at least 6 months, while the clinical study at Duke University (Duke) asked participants to use the app for at least 1 month. Eligible participants were all aged ≥18 years with a confirmed diagnosis of SCD.
For all participants, SMART was installed either on the patient's own iOS mobile device (iPad or iPhone) or one we provided, to track daily pain. Pain was recorded on a 0-10 visual analogue scale (VAS), with location of pain as a dropdown list. For each participant, a list of pharmacological interventions used was generated from current medications listed in medical records. Participants received push-notification reminders to record symptoms twice a day. Additional details on SMART are available (Shah et al, 2014; Jonassaint et al, 2015) .
T-tests and analyses of variance (ANOVAs) were used to compare the mean of the within-patient averaged pain levels. To account for within-patient correlation in the VAS pain reports, we fitted several linear mixed models, including both fixed effects for the independent variables and random effects at the patient and institution level. Multivariate models included as covariates: institution, gender, age, hydroxycarbamide use, folic acid use, long-and short-acting opioid use, and non-opioid pain medications. Time of day was assessed as a categorical variable.
The sample included 47 patients (mean age 33 AE 11Á6 years) from Duke (n = 19), Vanderbilt (n = 8) and Pitt (n = 20). Eight participants were excluded from analysis due to having ≤5 entries (n = 6) or because VAS pain reports never exceeded 0 (n = 2). As presented in Table I , the final analysed sample included 39 participants with various types of SCD, including type SS, SOarab, SC, Sb + and Sb 0 (n = 3, 7%). Most participants were prescribed hydroxycarbamide (69%) and folic acid (66%). In addition, the majority were treated with pain medications including long-acting narcotics (74%), short-acting narcotics (88%) and non-opioids (74%). The 8 excluded participants were younger, and less likely to be taking folic acid or short-acting opioids. Participants used the SMART app for 164Á6 AE 109Á6 days, with a mean of 67Á2 AE 60Á4 pain reports per participant. The most frequent reporting occurred between 18 and 24 h (n = 911) and the least frequent between 0 and 7 h (n = 221). Mean of pain scores over the total study period was 4Á7 AE 2Á1 (range 0-10). The median use of SMART was similar at each institution and there were no use differences by demographic or clinical factors. A rapid decline in reporting occurred between Week 1, with 7Á38 mean reports, and Week 6, with 3Á72 mean reports ( Figure S1 ). Reporting Linear mixed models showed genotype SC was associated with significantly lower mean VAS pain levels than either of the most severe genotypes SS or Sb 0 (b = 2Á15; P = 0Á04).
Using folic acid (regression coefficient (b) = À0Á39; P = 0Á04) and non-opioid pain medications (b = À2Á06; P = 0Á006) was also significantly associated with lower VAS pain level compared to not using those medications. There was a statistical trend toward use of short-acting opioids being associated with higher VAS pain level (b = 1Á33; P = 0Á09). There was no effect on VAS pain with regard to age, gender, hydroxycarbamide, long-acting opioids or institution differences. After controlling for the effect of other covariates, using folic acid (b = À0Á41, P = 0Á03) and nonopioids (b = À2Á25, P = 0Á004) was still significantly associated with lower VAS pain levels. Density plot of pain probability vs. time of day found a cluster of highest pain reports between 8 pm and 9 pm (Fig 1) . Highest probability of recording was found between 11 am and noon, with both higher and lower pain scores recorded frequently during this time.
On average, patients reported pain using an electronic pain diary app for about 6 months and entered data every 2-3 days. Several trends or significant associations in the expected direction help support the validity and accuracy of this data capture method. For instance, patients reported spikes in pain at night and those taking non-opioid pain medications had 2Á3/10 points lower average pain on the VAS, while those prescribed a short-acting opioid for pain had 1Á3/10 points higher average pain.
Like other remote symptom-reporting tools (Whitehead & Seaton, 2016) , app use was more frequent at the beginning of the reporting period and then decreased over time.
Further, there were significant individual differences in the frequency of reporting, with several individuals reporting fewer than five times and others reporting nearly every day. Future studies of SMART would benefit from strategies to increase engagement. We note, for example, that participants received no compensation or incentives for their daily reporting in any of these studies, thus there were no external incentives for engagement.
Despite a limited sample size, this study provides strong evidence supporting the use of mobile technology for measuring daily pain and symptoms in SCD. Ecological momentary assessment may be an effective and accurate means for evaluating treatment outcomes and pain trajectories in this population. Future studies using this methodological approach will help identify patient-specific differences in pain patterns and ultimately build prediction models for changes in SCD-related symptoms. 
